Vertex Pharma

At the Cantor Fitzgerald Healthcare Conference, Vertex announced plans to expand its business beyond cystic fibrosis into multiple pillars, focusing on pain, hematology, kidney diseases and rare endocrine disorders following the Crinetics acquisition. CASGEVY and JOURNAVX are expected to generate combined revenue of more than $500m in 2025; JOURNAVX already has 1.6m prescriptions in 2025 and access to 260m insured lives. The PDUFA date for povetacicept in IgA nephropathy is November 30, 2025; inaxaplin is progressing as planned in the phase‑III AMPLITUDE study with interim readouts in early 2027. Vertex emphasized strict acquisition criteria and sees peak sales potential of up to $5bn from Crinetics additions PALSONIFY and Atumelnant. » More on de.investing.com

Vertex is shifting to a broader business model and aims to grow beyond cystic fibrosis, particularly in kidney diseases. Key programs include Inaxaplin (AMPLITUDE) for APOL1-mediated diseases with an interim readout in Q1 2027, and Povetacicept for IgA nephropathy (PDUFA 30.11.2024). The integration of Crinetics adds PALSONIFY and Atumelnant to the portfolio; Vertex expects combined peak sales of about $5 billion and cites numerous catalysts over the next 12–24 months. JOURNAVX is showing prescription-side growth, but revenue realization remains temporarily dampened by reimbursement issues. » More on de.investing.com

Vertex Pharmaceuticals shares rose to an all-time high of $555.84, close to the 52-week high, with a market capitalization of about $139.72 billion. Over the past year the stock gained 39.95%, reflecting positive market sentiment and investor confidence. Several analysts reaffirmed or raised price targets (RBC $570, BMO $600, Bernstein SocGen $608, Wolfe Research $562) and highlighted potential beyond the cystic fibrosis business. However, an InvestingPro analysis classifies VRTX as overvalued relative to its fair value. » More on de.investing.com